This review summarizes the analytic and clinical issues regarding the selection and interpretation of cardiac biomarkers for the management of acute chest pain and suspected acute coronary syndrome.
Emphasizes pitfalls in biomarker selection for suspected ACS; leaves open standardization needs with evolving assays.
Cardiac markers are presently a hot topic, with active debate on their use. They now have a major role for cost-effective management of acute chest pain and suspected acute coronary syndrome. The laboratory has a pivotal role in proper selection and interpretation of available markers, depending on the creation of evidence-based knowledge about test utilization and sources of variation. This article reviews this knowledge in the field of biomarkers determination and summarizes the major analytic and clinical issues, with reference to various recent recommendations of laboratory medicine and cardiology expert groups.
No takes yet. Share an insight, caveat, or question.
Mauro Panteghini (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: